ReNeuron Group (LON:RENE) posted its quarterly earnings data on Friday. The company reported GBX (16.80) (($0.22)) EPS for the quarter, Digital Look Earnings reports.
LON RENE opened at GBX 54 ($0.71) on Friday. ReNeuron Group has a 52 week low of GBX 1.37 ($0.02) and a 52 week high of GBX 142.50 ($1.86).
In related news, insider Michael Hunt bought 7,462 shares of the stock in a transaction dated Thursday, September 27th. The stock was purchased at an average cost of GBX 67 ($0.88) per share, with a total value of £4,999.54 ($6,532.78).
ILLEGAL ACTIVITY WARNING: This piece was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this piece on another publication, it was illegally copied and republished in violation of international copyright law. The legal version of this piece can be viewed at https://sportsperspectives.com/2018/12/15/reneuron-group-rene-announces-quarterly-earnings-results.html.
ReNeuron Group plc develops and sells cell-based therapies in the United Kingdom. The company's lead therapeutic candidate is CTX stem cell therapy, which has been completed Phase II clinical trial for the treatment of patients living with chronic disability following stroke, as well as that has been completed Phase I clinical trial to treat limb ischaemia.
Further Reading: What is an SEC Filing?
Receive News & Ratings for ReNeuron Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReNeuron Group and related companies with MarketBeat.com's FREE daily email newsletter.